

Stock Data

Share Price: 22.50p
Market Cap: £35.1m
Shares in issue: 156.2m

Company Profile


Sector: Healthcare
Ticker: DVRG
Exchange: AIM

Activities

DeepVerge plc ('DeepVerge', 'DVRG', 'the Group'), (formerly Integumen plc) is a vertically integrated business, collaborating technology platforms with partners in artificial intelligence, clinical research, water technologies, medical devices and life science. These collaborators are building their own technology on top of the Labskin AI backbone. Labskin allows skincare, healthcare, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.

Group website: www.deepverge.com

Share price performance from 6 Oct.2020



Source: [LSE](#)

Past performance is not an indication of future performance.

Turner Pope contact details

Turner Pope Investments ('TPI') Limited
8 Frederick's Place
London EC2R 8AB

Tel: 0203 657 0050
Email: info@turnerpope.com
Web: www.turnerpope.com

Attention is drawn to the disclaimers and risk warnings at the end of this document.

This is a non-independent marketing communication. The analyst who has prepared this report is aware that TPI has a relationship with the company covered in this report. Accordingly, it has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

TPI acts as sole broker to DeepVerge plc. Retail clients (as defined by the rules of the FCA) must not rely on this document.

Barry Gibb
Research Analyst
Tel: 0203 657 0050
barry.gibb@turnerpope.com

Andrew Thacker
Corporate Broking & Sales
Tel: 0203 657 0050
andy.thacker@turnerpope.com

Zoe Alexander
Corporate Broking & Sales
Tel: 0203 657 0050
zoe.alexander@turnerpope.com

DeepVerge plc

As part of the extended field trial for DeepVerge's Microtox PD unit, its COVID-19 enabled near-source wastewater contamination test system, deployment into a number of Irish water treatment plants has now commenced. Similar arrangements across multiple sites in Northern England are also expected shortly with first shipments to China and the US following by the year-end. The data acquired through this exercise, combined with modelling through the Group's Rinocloud artificial intelligence division, is expected to offer potential to predict the growth trajectory of future coronavirus (or other dangerous pathogen) clusters, thereby providing an urgently needed, localised early warning system. Clearly, access to such unique technologies remains a key element for global populations seeking to return to some sort of post-Pandemic 'normality'. With the expectation that the Group will be able to successfully commercialise Microtox PD before H2 2021 followed by multinational roll-out through its established international customer network, DeepVerge's ability to adequately service the overwhelming international demand it prospectively faces may become the most significant challenge going forward as it seeks to satisfy what has potential to become an exceptionally rewarding, high-margin global opportunity.

Mass, real-time surveillance of wastewater pathogens

DeepVerge's collaborations with [Avacta Group](#) (to secure access to its highly sensitive [Affimer](#) reagents) and [Aptamer Group](#) (providing nano-scale coatings) resulted in the development of a unique, real-time SARS-CoV-2 identification and alert system for the detection of the coronavirus. Applied to wastewater detection, the product's first two validation phases were successfully completed initially through spike protein testing in filtered wastewater (at the Group's York laboratories), followed by full beta testing of the system using virus samples in the University of Aberdeen's level 3 containment ('CAT3') laboratory.

A third and final phase ahead of commercialisation in the form of field trials, is now getting underway at multiple sites in different geographical locations. Microtox PD units, retrofitted with AI based optofluidic pathogen identification scanners, are also being shipped to the University of Aberdeen's CAT3 laboratory, adding to the ongoing trials with the live SARS-CoV-2 supplied by Public Health England. In collaboration with EcoWaterOS consortia partners in Northern England, aggregated anonymised data will provide datasets for AI model simulations from human volunteers who will undergo COVID-19 testing with a combination of [Microtox BT](#) (DeepVerge's personalised rapid COVID-19 optofluidic breath test with interactive digital health pass platform), a lateral flow antigen test and a rt-PCR test.

Sufficient datasets from these field tests are anticipated to be available for analysis and processing early in 2021. These are expected to enable simultaneous identification of the source of COVID-19 cases and any associated clusters, indicating the size of each in real-time. With this growing volume of data, DeepVerge's Rinocloud data management and artificial intelligence division will then be able offer potential to predict the trajectory of growth of such future coronavirus (as well as any other dangerous pathogen) clusters.

Microtox BT breath test – Another step toward commercialisation

DeepVerge has also agreed to license a patented breathalyser from [PulMoBioMed Limited](#), a spin-out technology company of Northumbria University, to capture SARS-CoV-2 particles in breath condensate for its optofluidic breath test, Microtox BT. This is expected to speed roll out of the product once field trials have satisfactorily completed and regulatory authorities ([MHRA](#), [FDA](#), etc) have approved it for use as a [medical device](#).

THIS DOCUMENT IS NOT FOR PUBLICATION, DISTRIBUTION OR TRANSMISSION INTO THE UNITED STATES OF AMERICA, JAPAN, CANADA OR AUSTRALIA.

Conflicts

This is a non-independent marketing communication under the rules of the Financial Conduct Authority ("FCA"). The analyst who has prepared this report is aware that Turner Pope Investments (TPI) Limited ("TPI") has a relationship with the company covered in this report. Accordingly, the report has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing by TPI or its clients ahead of the dissemination of investment research.

TPI manages its conflicts in accordance with its conflict management policy. For example, TPI may provide services (including corporate finance advice) where the flow of information is restricted by a Chinese wall. Accordingly, information may be available to TPI that is not reflected in this document. TPI may have acted upon or used research recommendations before they have been published.

Risk Warnings

Retail clients (as defined by the rules of the FCA) must not rely on this document.

Any opinions expressed in this document are those of TPI's research analyst. Any forecast or valuation given in this document is the theoretical result of a study of a range of possible outcomes and is not a forecast of a likely outcome or share price.

The value of securities, particularly those of smaller companies, can fall as well as rise and may be subject to large and sudden swings. In addition, the level of marketability of smaller company securities may result in significant trading spreads and sometimes may lead to difficulties in opening and/or closing positions. Past performance is not necessarily a guide to future performance and forecasts are not a reliable indicator of future results.

AIM is a market designed primarily for emerging or smaller companies and the rules of this market are less demanding than those of the Official List of the UK Listing Authority; consequently AIM investments may not be suitable for some investors. Liquidity may be lower and hence some investments may be harder to realise.

Specific disclaimers

TPI acts as sole broker to DeepVerge plc ('DeepVerge') which is listed on the AIM Market of the London Stock Exchange ('AIM'). TPI's private and institutional clients may hold, subscribe for or buy or sell DeepVerge's securities.

Opinions and estimates in this document are entirely those of TPI as part of its internal research activity. TPI has no authority whatsoever to make any representation or warranty on behalf of DeepVerge.

General disclaimers

This document, which presents the views of TPI's research analyst, cannot be regarded as "investment research" in accordance with the FCA definition. The contents are based upon sources of information believed to be reliable but no warranty or representation, express or implied, is given as to their accuracy or completeness. Any opinion reflects TPI's judgement at the date of publication and neither TPI nor any of its directors or employees accepts any responsibility in respect of the information or recommendations contained herein which, moreover, are subject to change without notice. Any forecast or valuation given in this document is the theoretical result of a study of a range of possible outcomes and is not a forecast of a likely outcome or share price. TPI does not undertake to provide updates to any opinions or views expressed in this document. TPI accepts no liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection with this document (except in respect of wilful default and to the extent that any such liability cannot be excluded by applicable law).

The information in this document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.

This document is approved and issued by TPI for publication only to UK persons who are authorised persons under the Financial Services and Markets Act 2000 and to professional clients, as defined by Directive 2004/39/EC as set out in the rules of the Financial Conduct Authority. This document may not be published, distributed or transmitted to persons in the United States of America, Japan, Canada or Australia. This document may not be copied or reproduced or re-distributed to any other person or organisation, in whole or in part, without TPI's prior written consent.

Copyright © 2020 Turner Pope Investments (TPI) Limited, all rights reserved.